Adityo Prakash, CEO of Verseon, introduces a new mathematical approach to computing molecular interactions.  The objective of small-molecule drug discovery is to find binders to target proteins involved in disease processes. However, the discovery and development of novel small-molecule therapeutics remains one of the most resource-intensive endeavors in biomedical science. Conventional drug discovery relies on […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!